Abstract: A computer-implementation method for dataless contextual targeting includes the following steps. First, automatically crawling noisy labeled corpora from one or more sites using a category mapping from first categories to second categories. Second, applying one or more statistical methods to automatically mine representative keywords for each of the first categories from the noisy labeled corpora. Applying dataless classification learning to induce a text classifier with the automatically mined representative keywords and unlabeled web pages as input.

Abstract: A computer-implementation method for dataless contextual targeting includes the following steps. First, automatically crawling noisy labeled corpora from one or more sites using a category mapping from first categories to second categories. Second, applying one or more statistical methods to automatically mine representative keywords for each of the first categories from the noisy labeled corpora. Applying dataless classification learning to induce a text classifier with the automatically mined representative keywords and unlabeled web pages as input.

Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of EPA or DHA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of EPA or DHA (resolvins of the E series and D series) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.

Abstract: The method of diagnosing lesions of crystalline lens such as cataract is disclosed. It comprises detecting variation of crygs gene, transcript and/or protein of individuals compared with normalty. The individual suffers from cataract more possible than normalty when occurring the variation. The present invention also discloses the method and pharmaceutical composition of treating lesions of crystalline lens such as cataract.

Abstract: The invention relates to the field of microbial technology. It discloses a method to apply the cloud point system (CPS) in biotransformation by selecting one or more types of nonionic surfactant to form a aqueous system with a cloud point below the microbial transformation temperature, which serves as transformation medium. The method disclosed is suitable in particular for microbial transformation of hydrophobic compounds, for the system where substrate or product inhibits microbial growth or where product is further degraded by microbes. The CPS in the present invention forms a microemulsion of water-in-oil and oil-in-water, where the drops of surfactant is able to solubilize, serving as substrate reservoir and product extractant. This enhances bioavailability of substrates and elimination of product inhibition.

Abstract: The invention has disclosed a method for diagnosis of lens illnesses such as cataract. Said method comprises the steps of detecting the GRYGS gene, transcript and/or protein in said subject and comparing it with the normal GRYGS gene, transcript and/or protein to determine whether there is any variation, wherein said variation indicates that the possibility of suffering lens illnesses, such as cataract, in said subject is higher than that in the normal population. The present invention also discloses the method and pharmaceutical composition for treating cataract and other lens illnesses.